Pharmaceutical and Biotech Patent Disputes

English · Deutsch · Français

Pharmaceutical and biotechnology patent disputes often involve several layers of protection around one commercial product. Compound, formulation, process, dosage and medical-use claims can create different risks at different stages. Patent analysis must be coordinated with the actual development, regulatory, manufacturing and launch plan.

In this guide: Map the relevant rights and timelines · Analyse the claim category and intended use · Test validity and the disclosed technical effect · Plan evidence and urgent proceedings around launch · Address research, regulatory exceptions and settlement

Illustrative laboratory glass vials and pipettes in a modern laboratory

Map the relevant rights and timelines

Identify the patents, claims, priority dates, expiry, supplementary protection certificates and any extensions relevant to the product. Distinguish patent protection from regulatory data or market exclusivity. The expiry of one compound patent does not establish freedom to launch if other relevant rights remain. Check UPC competence, opt-outs and national rights separately. A reliable launch map should identify the legal obstacle associated with each product, indication, manufacturing route and territory.

Analyse the claim category and intended use

A formulation claim, manufacturing claim and purpose-limited medical-use claim require different factual comparisons. Review composition, dose, administration, patient group and the commercial presentation where relevant. Regulatory approval does not itself establish patent clearance. Conversely, a patent allegation must be connected to the claim’s technical and use limitations. Product labels, distribution arrangements and actual intended activity may all matter, depending on the right and applicable law.

Test validity and the disclosed technical effect

Life-sciences patents can raise questions of priority, sufficiency, inventive step and support for the asserted technical effect. Assess the application as filed, common general knowledge and the relevant experimental evidence. For further medical-use claims, the therapeutic effect forms part of the claimed subject matter and sufficiency requires particular attention. Later data cannot simply be assumed to repair every defect in the original disclosure. Expert evidence should explain the science and its legal relevance clearly.

Plan evidence and urgent proceedings around launch

Product samples, analytical methods, batch records and regulatory documents can be important. Preserve provenance and distinguish what a public document proves from what remains confidential or inferential. Consider preliminary-injunction risk, protective letters and targeted evidence measures before a launch becomes imminent. The urgency chronology and commercial consequences need supporting evidence. A compressed launch timetable makes earlier coordination between technical, regulatory and litigation teams especially valuable.

Address research, regulatory exceptions and settlement

Experimental and regulatory exceptions require analysis of the particular acts and applicable law; they should not be treated as a general licence for all pre-launch or commercial activity. Settlement may need to cover indications, formulations, manufacturing changes, suppliers and future regulatory approvals. Competition-law issues can also arise in pharmaceutical agreements. Define the permitted activity and any transition arrangements precisely, keeping patent rights and regulatory obligations distinct.

Four practical examples

These hypothetical examples explain typical decisions and evidence issues. They do not describe client matters or predict a court outcome.

1. Compound expiry does not end every risk

A generic manufacturer plans a launch after the main compound patent expires. It reviews formulation, process and medical-use claims and any relevant SPC position. The launch decision is based on the remaining rights and actual product, rather than the expiry date of the best-known patent alone.

2. A biosimilar uses a different production route

The final product is similar, but the manufacturing process differs from the asserted claim. The defendant preserves batch and development records and considers confidentiality protection before explaining the route. Product similarity is not treated as conclusive proof of the claimed process.

3. A therapeutic effect is challenged

An opponent argues that the original application did not sufficiently support the claimed medical use. The proprietor identifies the disclosed evidence and scientific reasoning available at the relevant date. Later studies are assessed within the applicable legal framework rather than assumed to cure any original insufficiency.

4. A settlement must cover future indications

The parties negotiate a licence for the current product, while additional indications are under development. They define whether those indications, revised formulations and manufacturing changes fall within the agreement. This prevents a settlement of today’s launch dispute from leaving an avoidable dispute over the next approval.

Related guidance

Preliminary Injunctions · Protective Letters · Product and Process Patents · EPO Oppositions and Appeals

Legal framework and sources

Articles 25–27, 30 and 62 UPCA; Articles 54, 56 and 83 EPC; applicable SPC and regulatory legislation.

UPC Agreement · EPO: further medical-use claims and sufficiency · EPO: first and further medical use

Discuss your patent matter

For an initial enquiry, identify the patent, the product or process and any known court or launch deadline. Please leave out confidential technical details until conflicts have been checked.